The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa
Open accessAbstract
BACKGROUND: Hydroxyurea is an effective treatment for sickle cell anemia, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in low-resource settings. METHODS: We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-Saharan countries. Children received hydroxyurea at a dose of 15 to 20 mg per kilogram of body weight per day for 6 months, followed by dose escalation. The end points assessed feasibility (enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and benefits (laboratory variables, sickle cell-related events, transfusions, and survival). RESULTS: A total of 635 children were fully enrolled; 606 children completed screening and began receiving hydroxyurea at a mean (±SD) dose of 17.5±1.8 mg per kilogram per day. The retention rate was 94.2% at 3 years of treatment. Hydroxyurea therapy led to significant increases in both the hemoglobin and fetal hemoglobin levels. Dose-limiting toxic events regarding laboratory variables occurred in 5.1% of the participants, which was below the protocol-specified threshold for safety. During the treatment phase, 20.6 dose-limiting toxic effects per 100 patient-years occurred, as compared with 20.7 events per 100 patient-years before treatment. As compared with the pretreatment period, the rates of clinical adverse events decreased with hydroxyurea use, including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patient-years; incidence rate ratio, 0.45; 95% confidence interval [CI], 0.37 to 0.56), nonmalaria infection (142.5 vs. 90.0 events per 100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72), malaria (46.9 vs. 22.9 events per 100 patient-years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), transfusion (43.3 vs. 14.2 events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and death (3.6 vs. 1.1 deaths per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88). CONCLUSIONS: Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive events, infections, malaria, transfusions, and death, which supports the need for wider access to treatment. (Funded by the National Heart, Lung, and Blood Institute and others; REACH ClinicalTrials.gov number, NCT01966731 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, an open-label trial in 606 African children aged 1 to 10 years treated with hydroxyurea found that HbF increased from 10.9% to 23.4%.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was associated with a decrease in the rate of malaria infection by more than 60%.73”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [73]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hydroxyurea is also used effectively in low-resource countries.73,79,80”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Self-citationPopulation Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,214
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Dewi, M., Temperley, W. H., Williams, T. N., Weatherall, D. J., & Hay, S. I. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61229-x · Cited by 1,196
Self-citationWare, R. E., de Montalembert, M., Tshilolo, L. M., & Abboud, M. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30193-9 · Cited by 1,036
Self-citationImproved survival of children and adolescents with sickle cell disease
Quinn, C. T., Rogers, Z. R., McCavit, T. L., & Buchanan, G. R. (2010) · Blood · doi:10.1182/blood-2009-07-233700 · Cited by 904
Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803
Self-citationGrosse, S. D., Odame, I., Atrash, H. K., Amendah, D. D., Piel, F. B., & Williams, T. N. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.09.013 · Cited by 710
Self-citationHydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B. A., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 532
Ware, R. E., Davis, B. R., Schultz, W. H., Brown, R. C., Aygun, B., Sarnaik, S., Odame, I., Fuh, B., George, A., Owen, W., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01041-7 · Cited by 515
Self-citationPrediction of Adverse Outcomes in Children with Sickle Cell Disease
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420203 · Cited by 508
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 406
Self-citationTelfer, P. T., Coen, P. G., Chakravorty, S., Wilkey, O., Evans, J. P. M., Newell, H., Smalling, B., Amos, R. I. J., Stephens, A. D., Rogers, D., et al. (2007) · Haematologica · doi:10.3324/haematol.10937 · Cited by 356
Zimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., & Ware, R. E. (2003) · Blood · doi:10.1182/blood-2003-07-2475 · Cited by 312
Self-citationNdeezi, G., Kiyaga, C., Hernandez, A. G., Munube, D., Howard, T. A., Ssewanyana, I., Nsungwa, J., Kiguli, S., Ndugwa, C. M., Ware, R. E., et al. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(15)00288-0 · Cited by 209
Self-citationLê, P.-Q., Gulbis, B., Dedeken, L., Dupont, S., Vanderfaeillie, A., Heijmans, C., Huybrechts, S., Devalck, C., Efira, A., Dresse, M., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25608 · Cited by 164
The effect of hydroxcarbamide therapy on survival of children with sickle cell disease
Lobo, C. L. D. C., Pinto, J. F. D. C., do Nascimento, E. M., de Moura, P. G., Cardoso, G. P., & Hankins, J. S. (2013) · British Journal of Haematology · doi:10.1111/bjh.12323 · Cited by 163
Opoka, R. O., Ndugwa, C. M., Latham, T., Lane, A., Hume, H. A., Kasirye, P., Hodges, J. S., Ware, R. E., & John, C. C. (2017) · Blood · doi:10.1182/blood-2017-06-788935 · Cited by 151
Self-citationMcAuley, C. F., Webb, C., Makani, J., Macharia, A. W., Uyoga, S. M., Opi, D. H., Ndila, C., Ngatia, A., Scott, J. A. G., Marsh, K., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265249 · Cited by 139
Self-citationA prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola
McGann, P. T., Ferris, M. G., Ramamurthy, U., Santos, B., de Oliveira, V., Bernardino, L., & Ware, R. E. (2013) · American Journal of Hematology · doi:10.1002/ajh.23578 · Cited by 118
Self-citationMcGann, P. T., Hernandez, A. G., & Ware, R. E. (2016) · Blood · doi:10.1182/blood-2016-09-702324 · Cited by 111
Self-citationThornburg, C. D., Dixon, N., Burgett, S. E., Mortier, N. A., Schultz, W. H., Zimmerman, S. A., Bonner, M. J., Hardy, K. K., Calatroni, A., & Ware, R. E. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21738 · Cited by 96
Self-citationIs Sickle Cell Anemia a Neglected Tropical Disease?
Ware, R. E. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002120 · Cited by 75
Self-citationMcGann, P. T., Tshilolo, L. M., Santos, B., TOMLINSON, G. A., Stuber, S. E., Latham, T., Aygün, B., Obaro, S., Olupot‐Olupot, P., Williams, T. N., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25705 · Cited by 67
Self-citationLagunju, I. A., Brown, B. J., & Sodeinde, O. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25529 · Cited by 64
High birth prevalence of sickle cell disease in Northwestern Tanzania
Ambrose, E. E., Makani, J., Chami, N., Masoza, T. S., Kabyemera, R., Peck, R. N., Kamugisha, E., Manjurano, A. M., Kayange, N., & Smart, L. R. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26735 · Cited by 53
Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea
Lagunju, I., Brown, B. J., & Sodeinde, O. (2013) · Nigerian Postgraduate Medical Journal · doi:10.4103/1117-1936.164707 · Cited by 38
Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models
Pino, P., Taoufiq, Z., BRUN, M., Tefit, M., Franetich, J., Cicéron, L., Krishnamoorthy, R., & Mazier, D. (2006) · Parasite Immunology · doi:10.1111/j.1365-3024.2006.00907.x · Cited by 31
Foetal haemoglobin and the dynamics of paediatric malaria
Billig, E., McQueen, P. G., & McKenzie, F. E. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-396 · Cited by 30
Clinical Features of β-Thalassemia and Sickle Cell Disease
McGann, P. T., Nero, A. C., & Ware, R. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_1 · Cited by 29
Self-citationNdila, C., Bauni, E., Nyirongo, V. B., Mochamah, G., Makazi, A. B., Kosgei, P., Nyutu, G., Macharia, A., Kapesa, S., Byass, P., et al. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-65 · Cited by 25
Self-citationKing, L. G. C., Ali, S. B., Cunningham-Myrie, C. A., & Reid, M. E. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.06.028 · Cited by 24
Fixed low‐dose hydroxyurea for the treatment of adults with sickle cell anemia in N igeria
Tayo, B. O., Akingbola, T. S., Saraf, S. L., Shah, B. N., Ezekekwu, C. A., Sonubi, O., Hsu, L. L.-Y., Cooper, R., & Gordeuk, V. R. (2018) · American Journal of Hematology · doi:10.1002/ajh.25143 · Cited by 15
The future of transfusion and A frica
Dzik, S., & Delaney, M. (2014) · Transfusion · doi:10.1111/trf.12823 · Cited by 9
Flagged first, then by citations
Cited by
Sorted by citations
Thomson, A. M., McHugh, T. A., Oron, A. P., Teply, C., Lonberg, N., Vilchis-Tella, V. M., Wilner, L. B., Fuller, K. C., Hagins, H., Aboagye, R. G., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00118-7 · Cited by 815
DeBaun, M. R., Jordan, L. C., King, A. A., Schatz, J. C., Vichinsky, E. P., Fox, C. K., McKinstry, R. C., Telfer, P. T., Kraut, M. A., Daraz, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001142 · Cited by 447
Recent Advances in the Treatment of Sickle Cell Disease
Cisneros, G. S., & Thein, S. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00435 · Cited by 210
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O. E., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 203
Self-citationHydroxyurea dose escalation for sickle cell anemia in Sub-Saharan Africa
John, C. C., Opoka, R. O., Latham, T. S., Hume, H. A., Nabaggala, C., Kasirye, P., Ndugwa, C. M., Lane, A., & Ware, R. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2000146 · Cited by 153
Self-citation
Metadata
- Authors
- Tshilolo, L., Tomlinson, G., Williams, T. N., Santos, B., Olupot-Olupot, P., Lane, A., Aygun, B., Stuber, S. E., Latham, T. S., McGann, P. T., & Ware, R. E.
- Affiliations
- Mount Sinai Hospital (CA)
- From Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo (L.T.); the Department of Medicine, University Health Network and Mt. Sinai Hospital, and the University of Toronto, Toronto (G.T.); the Kenya Medical Research Institute (KEMRI)–Wellcome Trust Research Program, Kilifi, Kenya (T.N.W.); the Department of Medicine, Imperial College London, London (T.N.W.); Hospital Pediátrico David Bernardino, Luanda, Angola (B.S.); Mbale Clinical Research Institute and Mbale Regional Referral and...
- Cincinnati Children's Hospital Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-10
- Volume
- 380
- Issue
- 2
- Pages
- 121-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6454575
- OpenAlex
- W2902147263
- Semantic Scholar
- c678f2b17bd36f38a14c64ccd2a41b9165ece5b3
- Cited by
- 376
- References
- 38
- Citations by year
- 2026: 47 · 2025: 50 · 2024: 49 · 2023: 77 · 2022: 48 · 2021: 37 · 2020: 37 · 2019: 31
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23 HL128885, U01 HL133883)
- Cincinnati Children’s Research Foundation (None)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Keywords
- hydroxyurea, sickle cell disease, pediatric patients, sub-Saharan Africa, resource-limited settings, malaria, vaso-occlusive pain, transfusion requirements, fetal hemoglobin, hemoglobin levels, drug safety, medication adherence, dose escalation, malnutrition, survival, treatment retention, dose-limiting toxicity, malaria prophylaxis, hydroxyurea resistance
- MeSH terms
- Anemia, Sickle Cell, Antisickling Agents, Child, Child, Preschool, Dose-Response Relationship, Drug, Humans, Hydroxyurea, Infant, Malaria, Pain, Africa South of the Sahara, Neglected Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
